A phase 1 open-label trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of subcutaneous VIS171 in participants with autoimmune disease(s).

• Protocol code: VIS171-103
• EudraCT code: _
• Research group: Nephrology and kidney transplantation
• Service: Nephrology
• Principal investigator:  Sans Atxer, Laia
• Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
• Phase: Fase I